STC2 and prostate adenocarcinoma: The results showed that the STC2 expression levels was significantly correlated with immune score in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) (r = 0.34, p = 0.017), KICH (r = 0.38, p = 0.0018), MESO (r = 0.32, p = 0.0024), pancreatic adenocarcinoma (PAAD) (r = 0.36, p < 0.001), pheochromocytoma and paraganglioma (PCPG) (r = 0.54, p < 0.001), and PRAD (r = 0.31, p < 0.001).